Dickstein K, Kjekshus J
Cardiology Division, Central Hospital in Rogaland, Stavanger, Norway.
Am J Cardiol. 2001 Mar 15;87(6):766-71, A7. doi: 10.1016/s0002-9149(00)01500-9.
The OPTIMAAL study was a multicenter, double-blind, randomized, parallel, trial in high-risk patients who were treated early after acute myocardial infarction that compared treatment with an angiotensin-converting enzyme inhibitor (captopril) and a selective angiotensin II antagonist (losartan) on survival and morbidity. A total of 5,477 patients with heart failure during the acute phase or with a new Q-wave anterior infarction or reinfarction were recruited. This study describes the baseline data and initial course of the cohort and compares these data and patient management across countries.
OPTIMAAL研究是一项多中心、双盲、随机、平行试验，针对急性心肌梗死后早期接受治疗的高危患者，比较使用血管紧张素转换酶抑制剂（卡托普利）和选择性血管紧张素II拮抗剂（氯沙坦）治疗对生存和发病率的影响。总共招募了5477例在急性期出现心力衰竭、新发Q波前壁梗死或再梗死的患者。本研究描述了该队列的基线数据和初始病程，并比较了不同国家的这些数据及患者管理情况。
